The immunomodulatory and neurotoxic activities of kynurenines derived from tryptophan catabolism by indoleamine-2,3-dioxygenase (IDO1) play a role in sustaining a cycle of inflammation and immune dysfunction during HIV infection. Such a cycle may lead to increased risks of non-AIDS diseases, such as liver disease and neurocognitive impairment, despite effective cART. We hypothesized that inhibition of IDO1 may break this cycle, reversing immune dysfunction, decreasing systemic inflammation, and ultimately decreasing the incidence of non-AIDS diseases. We tested this hypothesis in a pilot study of virologically suppressed, SIV-infected rhesus macaques treated with an optimized regimen of an IDO1 inhibitor (IDOi) currently under clinical investigation (INCB024360).
Twelve rhesus macaques were infected with SIVmac251, treated with cART, and divided into two groups after virologic suppression to receive either placebo or IDOi for 8 weeks while continuing ART. Blood, lymphatic tissue, and mucosal tissues were evaluated to determine the pharmacologic, immunologic, metabolic, microbiological, and transcriptomic features of IDOi during SIV infection.
SIV infection increased plasma levels of kynurenine even after ART and kynurenine was transiently suppressed after each IDOi dose. Pharmacologic inhibition of IDO1 led to increased CD4/CD8 ratio in blood and significantly decreased markers of T cell and monocyte activation in blood and lymphoid tissues. In gut mucosa, we observed a trend to increased frequency of CD4+ T cells producing IL-17, IL-22, and/or IL-21. Interestingly, we found increased plasma levels of microbial metabolites of tryptophan, such as indoleacetate, which are AHR agonists that promote intestinal barrier function through induction of IL-22 and have neuroprotective properties.
These results support the hypothesis that IDOi disrupts the vicious cycle of IDO1-mediated inflammation and immune dysfunction during SIV infection. This effect is associated with a shift in microbiota function characterized by increased production of anti-inflammatory postbiotic metabolites that may serve as novel biomarkers of disease and therapeutic responses. These data suggest further investigation of IDOi as a strategy to blunt or prevent non-AIDS diseases in suppressed HIV infection by targeting host and microbial metabolism in the setting of chronic inflammation.